NextCure (NXTC) to Release Earnings on Thursday

by · The Cerbat Gem

NextCure (NASDAQ:NXTC – Get Free Report) is expected to be announcing its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect the company to announce earnings of ($2.26) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 12, 2026 at 5:00 PM ET.

NextCure Price Performance

Shares of NASDAQ NXTC opened at $12.52 on Tuesday. The stock has a market capitalization of $43.90 million, a PE ratio of -0.52 and a beta of 1.54. NextCure has a one year low of $2.69 and a one year high of $15.74. The business’s fifty day moving average price is $12.72 and its 200-day moving average price is $9.92.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on NXTC shares. Wall Street Zen upgraded shares of NextCure to a “hold” rating in a research note on Saturday, December 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NextCure in a research report on Wednesday, January 28th. Finally, LADENBURG THALM/SH SH upgraded NextCure from a “neutral” rating to a “buy” rating and set a $18.00 price objective on the stock in a research note on Friday, November 7th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

View Our Latest Report on NXTC

Institutional Investors Weigh In On NextCure

Several hedge funds have recently bought and sold shares of NXTC. Cable Car Capital LP increased its position in shares of NextCure by 13.1% during the second quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after buying an additional 88,040 shares during the period. Affinity Asset Advisors LLC grew its holdings in shares of NextCure by 28.9% during the 4th quarter. Affinity Asset Advisors LLC now owns 247,294 shares of the company’s stock worth $3,509,000 after acquiring an additional 55,412 shares during the period. Ikarian Capital LLC bought a new position in shares of NextCure in the 4th quarter worth approximately $3,382,000. Squadron Capital Management LLC purchased a new position in shares of NextCure in the 4th quarter valued at approximately $3,363,000. Finally, Exome Asset Management LLC bought a new stake in shares of NextCure during the fourth quarter valued at approximately $2,341,000. 42.65% of the stock is currently owned by institutional investors.

NextCure Company Profile

(Get Free Report)

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.

Further Reading